¼¼°èÀÇ ÀǾàǰ ºÎÇüÁ¦ ½ÃÀå(2024-2030³â)
Pharmaceutical Excipients Market, Global, 2024-2030
»óǰÄÚµå : 1763031
¸®¼­Ä¡»ç : Frost & Sullivan
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 77 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,934,000
Web Access (Regional License) help
Frost & SullivanÀÇ À¥»çÀÌÆ® ·Î±×ÀÎ ÆÐ½º¿öµå°¡ ¹ßÇàµÇ¸ç, PDF¸¦ ´Ù¿î·Îµå ¹Þ´Â ÇüÅ·ΠÁ¦°øµÉ ¿¹Á¤ÀÔ´Ï´Ù. PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù


Çѱ۸ñÂ÷

ÀǾàǰÀÇ ¿ëÇØµµ, ¾ÈÁ¤¼º, »ýüÀÌ¿ë·ü, ÄÄÇöóÀ̾𽺸¦ Çâ»ó½ÃŰ´Â ºÎÇüÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ȯÀÚ Á᫐ Á¦Á¦°¡ ±Þ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

Frost & SullivanÀÇ º¸°í¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA) µî ÁÖ¿ä Áö¿ª ½ÃÀåÀ» Áß½ÉÀ¸·Î Àü ¼¼°è ÀǾàǰ ºÎÇüÁ¦ ½ÃÀåÀ» ºÐ¼®ÇÕ´Ï´Ù. °æ±¸¿ë ºÎÇüÁ¦, ÁÖ»çÁ¦ ºÎÇüÁ¦, ±¹¼Ò¿ë ºÎÇüÁ¦, ÈíÀÔ¿ë ºÎÇüÁ¦, ¾È°ú¿ë ºÎÇüÁ¦ µî ´Ù¾çÇÑ ºÎ¹®¿¡ ´ëÇÑ Á¤¼ºÀû, Á¤·®Àû ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. °æ±¸¿ë ºÎÇüÁ¦ ºÎ¹®Àº ´Ù½Ã °æ±¸¿ë °íü¿Í °æ±¸¿ë ¾×ü·Î ¼¼ºÐÈ­µË´Ï´Ù. Àα¸ °í·ÉÈ­¿Í Áúº´ Áõ°¡·Î ÀÎÇØ ¸ðµç Ä¡·á ¿µ¿ª¿¡¼­ ´Ù¾çÇÑ ÀǾàǰ Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °æ±¸ Åõ¿©´Â ºñ¿ë È¿À²¼º°ú ȯÀÚÀÇ ¼øÀÀµµ Çâ»óÀ¸·Î ÀÎÇØ °¡Àå ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ¿¹Ãø ±â°£ Áß ÈíÀÔ Åõ¿©°¡ °¡Àå Å« ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¿¬±¸´Â ¿¹Ãø ±â°£ Áß »ê¾÷À» Çü¼ºÇÏ´Â ½ÃÀå ¿ªÇп¡ ´ëÇÑ Ã¶ÀúÇÑ ÀÌÇØ¸¦ Á¦°øÇÕ´Ï´Ù. ½ÃÀå ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀ» ºÐ¼®Çϰí ÀÌ ºÐ¾ßÀÇ º¯È­·Î ÀÎÇÑ ±âȸ¸¦ ½Äº°ÇÏ¿© ½ÃÀå ±â¾÷°ú ÀÌÇØ °ü°èÀÚ°¡ Ȱ¿ëÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. º¸°í¼­ÀÇ ±âÁØ ¿¬µµ´Â 2024³âÀ̸ç, ¿¹Ãø ±â°£Àº 2025-2030³âÀÔ´Ï´Ù.

¸ñÂ÷

¼ºÀå ±âȸ : Á¶»ç ¹üÀ§

¼ºÀå ȯ°æ : ÀǾàǰ ºÎÇüÁ¦ ½ÃÀå¿¡¼­ÀÇ Æ®·£½ºÆ÷¸ÞÀ̼Ç

ÀǾàǰ ºÎÇüÁ¦ ½ÃÀåÀÇ ¿¡ÄڽýºÅÛ

ÀǾàǰ ºÎÇüÁ¦ ½ÃÀåÀÇ ¼ºÀå Á¦³Ê·¹ÀÌÅÍ

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : °æ±¸Åõ¿©¿ë ºÎÇüÁ¦

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : ÁÖ»ç¿ë ºÎÇüÁ¦

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : ±¹¼Ò¿ë ºÎÇüÁ¦

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : ÈíÀÔ¿ë ºÎÇüÁ¦

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : ¾È°ú¿ë ºÎÇüÁ¦

ÀǾàǰ ºÎÇüÁ¦ ½ÃÀåÀÇ ¼ºÀå ±âȸ À¯´Ï¹ö½º

ºÎ·Ï°ú ´ÙÀ½ ½ºÅÜ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Patient-centric Formulations are Experiencing Transformational Growth Due to Increased Demand for Excipients that Improve Drug Solubility, Stability, Bioavailability, and Compliance

This Frost & Sullivan report analyzes the global pharmaceutical excipients market, with a focus on key regional markets, including North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa (MEA). The report provides both qualitative and quantitative analyses of various segments, including oral dosage excipients, injectable excipients, topical excipients, inhalable excipients, and ophthalmic excipients. The oral dosage excipients segment is further divided into the oral solid excipients and oral liquid excipients. Population aging, combined with a rising prevalence of diseases, is driving demand for diverse drug dosage formulations across all therapeutic areas. The oral route of drug administration is the most preferred due to its cost-effectiveness and better patient compliance. However, the inhalable route is expected to account for the most significant growth during the forecast period. This study offers a thorough understanding of the market dynamics that will shape the industry over the forecast period. It analyzes the factors driving and restraining market growth and identifies opportunities that arise from the changes in this space for market players and stakeholders to leverage. The base year for this report is 2024, while the forecast period extends from 2025 to 2030.

Table of Contents

Growth Opportunities: Research Scope

Growth Environment: Transformation in the Pharmaceutical Excipients Market

Ecosystem in the Pharmaceutical Excipients Market

Growth Generators in the Pharmaceutical Excipients Market

Growth Generator: Oral Dosage Excipients

Growth Generator: Injectable Excipients

Growth Generator: Topical Excipient

Growth Generator: Inhalable Excipients

Growth Generator: Ophthalmic Excipients

Growth Opportunity Universe in the Pharmaceutical Excipients Market

Appendix & Next Steps

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â